|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ABII 10-K filed Mar 31, 2008. We have been operating at a loss. We have experienced significant operating losses in each year of our business. We had a net loss of approximately $41.6 million, $124.6 million and $12.7 million for years ended December 31, 2007, 2006 and 2005, respectively. We expect to incur additional operating losses for the foreseeable future until we generate sufficient Abraxane® revenues to offset our research and development activities to support our continuing product development efforts. This excerpt taken from the ABII 8-K filed Nov 8, 2007. We have been operating at a loss. We have experienced significant operating losses in each year of our business. We had a net loss of approximately $19.6 million, $124.6 million and $12.7 million for the six months ended June 30, 2007 and the years ended December 31, 2006 and 2005, respectively. We expect to incur additional operating losses for the foreseeable future until we generate sufficient Abraxane® revenues to offset our research and development activities to support our continuing product development efforts. | EXCERPTS ON THIS PAGE:
|
| |||||||